News & Updates

Show Multimedia Only

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

17 Jul 2025

Combination treatment with bevacizumab plus erlotinib appears to work against hereditary leiomyomatosis and renal-cell cancer (HLRCC)-associated or sporadic papillary renal-cell carcinoma, according to an open-label phase II study.

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

17 Jul 2025

Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD

17 Jul 2025 by

Intranasal esketamine, administered at two fixed doses as monotherapy for treatment-resistant depression (TRD), has demonstrated robust and rapid efficacy in a phase IV double-blind, placebo-controlled randomized trial.

Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD

17 Jul 2025

Hepatic steatosis linked to lower mortality in CLD patients

16 Jul 2025

The presence of substantial hepatic steatosis estimated by controlled attenuated parameter (CAP) score among patients who underwent vibration-controlled transient elastography (VCTE) appears to reduce the risk of all-cause mortality and decompensation, particularly in those with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Hepatic steatosis linked to lower mortality in CLD patients

16 Jul 2025

Oral frailty tied to worse physical, mental health in older adults

16 Jul 2025 by

Oral frailty can lead to negative outcomes in older adults, including poorer physical health and reduced cognition, according to a study. Early identification can help prevent these harmful consequences.

Oral frailty tied to worse physical, mental health in older adults

16 Jul 2025

Ustekinumab improves outcomes in UC patients

16 Jul 2025

Treatment with ustekinumab can help patients with ulcerative colitis (UC) achieve clinical and endoscopic outcomes of importance after 12 months, results of a real-world study have shown.

Ustekinumab improves outcomes in UC patients

16 Jul 2025

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

16 Jul 2025

Effective antiviral therapy is crucial for achieving sustained viral clearance and improving outcomes in patients with COVID-19, particularly among immunocompromised individuals.

At the recent ESCMID Global 2025 in Vienna, Austria, Ruth Mokgokong, a pharmacologist at Pfizer, UK, presented findings from the EPIC-IC trial, highlighting the benefits of an extended nirmatrelvir-ritonavir regimen in severely immunocompromised patients with symptomatic COVID-19.

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

16 Jul 2025

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

16 Jul 2025 by

A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

16 Jul 2025

BMI mediates link between diabetes, food insecurity

15 Jul 2025

A recent study has shown the significant role that BMI plays in the relationship between food insecurity and diabetes.

BMI mediates link between diabetes, food insecurity

15 Jul 2025

Exercise prevents death in diabetes patients with MI

15 Jul 2025 by

Regularly engaging in any physical activity (PA) can help reduce the risk of death in patients with diabetes and myocardial infarction (MI), suggests a study presented at ADA 2025.

Exercise prevents death in diabetes patients with MI

15 Jul 2025

Initial vision, infiltrate size predict outcomes in microbial keratitis

15 Jul 2025

Several factors contribute to the risk for worse 90-day best-corrected visual acuity (BCVA) in patients with microbial keratitis (MK), and these include initial vision, longer time until presentation, and larger infiltrate size, reports a study.

Initial vision, infiltrate size predict outcomes in microbial keratitis

15 Jul 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD

Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD

Hepatic steatosis linked to lower mortality in CLD patients

Hepatic steatosis linked to lower mortality in CLD patients

Oral frailty tied to worse physical, mental health in older adults

Oral frailty tied to worse physical, mental health in older adults

Ustekinumab improves outcomes in UC patients

Ustekinumab improves outcomes in UC patients

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

BMI mediates link between diabetes, food insecurity

BMI mediates link between diabetes, food insecurity

Exercise prevents death in diabetes patients with MI

Exercise prevents death in diabetes patients with MI

Initial vision, infiltrate size predict outcomes in microbial keratitis

Initial vision, infiltrate size predict outcomes in microbial keratitis